Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Guardant Health, Inc. (NASDAQ:GH) have been given an average rating of “Moderate Buy” by the twenty-four brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and twenty-three have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $77.1429.

Several research firms have recently commented on GH. Barclays lifted their price objective on shares of Guardant Health from $70.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Wolfe Research raised Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price target for the company in a research report on Thursday, September 25th. JPMorgan Chase & Co. boosted their price target on Guardant Health from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. Cowen restated a “buy” rating on shares of Guardant Health in a research note on Thursday, October 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research report on Wednesday, October 8th.

Insider Transactions at Guardant Health

In other news, insider John G. Saia sold 8,996 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $96.25, for a total value of $865,865.00. Following the sale, the insider owned 43,172 shares in the company, valued at $4,155,305. This represents a 17.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Helmy Eltoukhy sold 300,000 shares of the business’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the transaction, the chief executive officer owned 2,123,499 shares of the company’s stock, valued at $126,242,015.55. This represents a 12.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 313,161 shares of company stock worth $18,996,062 over the last 90 days. 6.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. TD Waterhouse Canada Inc. raised its stake in Guardant Health by 3.2% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock worth $306,000 after acquiring an additional 151 shares in the last quarter. Signaturefd LLC boosted its stake in Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after acquiring an additional 213 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Guardant Health by 0.3% during the first quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock worth $4,439,000 after purchasing an additional 282 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Guardant Health by 8.3% during the third quarter. PNC Financial Services Group Inc. now owns 4,016 shares of the company’s stock worth $251,000 after purchasing an additional 307 shares in the last quarter. Finally, IFP Advisors Inc increased its position in shares of Guardant Health by 120.1% during the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after purchasing an additional 334 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Guardant Health Stock Performance

Guardant Health stock opened at $108.13 on Monday. The stock has a market cap of $13.63 billion, a PE ratio of -33.68 and a beta of 1.56. The stock has a 50-day moving average of $80.11 and a two-hundred day moving average of $61.13. Guardant Health has a one year low of $29.91 and a one year high of $112.43.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.09. Guardant Health’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.88) EPS. Guardant Health has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Guardant Health will post -2.9 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.